169 related articles for article (PubMed ID: 20570038)
1. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.
Zhang X; Markovic-Plese S
Clin Neurol Neurosurg; 2010 Sep; 112(7):641-5. PubMed ID: 20570038
[TBL] [Abstract][Full Text] [Related]
2. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
3. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
Zhang X; Jin J; Tang Y; Speer D; Sujkowska D; Markovic-Plese S
J Immunol; 2009 Mar; 182(6):3928-36. PubMed ID: 19265172
[TBL] [Abstract][Full Text] [Related]
4. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis.
Ramgolam VS; Markovic-Plese S
Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):161-7. PubMed ID: 20384573
[TBL] [Abstract][Full Text] [Related]
6. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis.
Zhang X; Tao Y; Troiani L; Markovic-Plese S
J Immunol; 2011 Sep; 187(6):3431-7. PubMed ID: 21856936
[TBL] [Abstract][Full Text] [Related]
8. Properties and origin of human Th17 cells.
Romagnani S; Maggi E; Liotta F; Cosmi L; Annunziato F
Mol Immunol; 2009 Nov; 47(1):3-7. PubMed ID: 19193443
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
10. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis.
Schwab N; Zozulya AL; Kieseier BC; Toyka KV; Wiendl H
J Immunol; 2010 May; 184(9):5368-74. PubMed ID: 20357264
[TBL] [Abstract][Full Text] [Related]
11. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
[TBL] [Abstract][Full Text] [Related]
12. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease.
Brereton CF; Sutton CE; Lalor SJ; Lavelle EC; Mills KH
J Immunol; 2009 Aug; 183(3):1715-23. PubMed ID: 19570828
[TBL] [Abstract][Full Text] [Related]
15. The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T cells.
Crome SQ; Wang AY; Kang CY; Levings MK
Eur J Immunol; 2009 Jun; 39(6):1480-93. PubMed ID: 19449310
[TBL] [Abstract][Full Text] [Related]
16. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
17. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis.
Mus AM; Cornelissen F; Asmawidjaja PS; van Hamburg JP; Boon L; Hendriks RW; Lubberts E
Arthritis Rheum; 2010 Apr; 62(4):1043-50. PubMed ID: 20131264
[TBL] [Abstract][Full Text] [Related]
20. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
